Eighteen nucleic acid therapeutics have been approved for treatment of various diseases in
the last 25 years. Their modes of action include antisense oligonucleotides (ASOs), splice …

The ability of chemical modifications of single nucleotides to alter the electrostatic charge,
hydrophobic surface and base pairing of RNA molecules is exploited for the clinical use of …

Peptide-based materials that have diverse structures and functionalities are an important
type of biomaterials. In former times, peptide-based nanomaterials with excellent stability …

Owing to specific and compelling gene silencing, RNA interference (RNAi) is expected to
become an essential approach in treating a variety of infectious, hemato-oncological …

The advent of genome editing has transformed the therapeutic landscape for several
debilitating diseases, and the clinical outlook for gene therapeutics has never been more …

Cancer immunotherapy is revolutionizing oncology. However, dose-limiting toxicities and
low patient response rates remain major challenges in the clinic. Cancer nanomedicine in …

The first published description of therapeutic applications of antisense oligonucleotide
(ASO) technology occurred in the late 1970s and was followed by the founding of …

Antisense oligonucleotides (ASOs) bind sequence specifically to the target RNA and
modulate protein expression through several different mechanisms. The ASO field is an …

Using the DNA origami technique, we constructed a DNA nanodevice functionalized with
small interfering RNA (siRNA) within its inner cavity and the chemotherapeutic drug …

Nanoparticles have been widely applied as gene carrier for improving RNA interference
(RNAi) efficiency in medical and agricultural fields. However, the mechanism and delivery …